Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sitagliptin q.d./metformin ≥ /day · 1 trial · 1 indication
A1C was measured as a percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.
| Arm | Type | Description |
|---|---|---|
| sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day | EXPERIMENTAL | - |
| sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day | DRUG | Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets. |
| comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day | DRUG | Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets. |
Inclusion Criteria: * Patient has type 2 diabetes mellitus * Males * Females who are highly unlikely to become pregnant * Patients poorly controlled while taking one or two oral antidiabetic medications Exclusion Criteria: * Patient has a history of type 1 diabetes mellitus or history of ketoacid...
Sitagliptin q.d.+ Pioglitazone q.d is an investigational combination of two small-molecule drugs being studied for the treatment of Type 2 Diabetes Mellitus (T2DM). It is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 3 clinical development.
Sitagliptin q.d.+ Pioglitazone q.d is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting Phase 3 clinical trials to evaluate this combination therapy for Type 2 Diabetes Mellitus.
Sitagliptin q.d.+ Pioglitazone q.d is in Phase 3 clinical development. It is an investigational combination therapy for Type 2 Diabetes Mellitus and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, with a total enrollment of 837 patients.
Sitagliptin q.d.+ Pioglitazone q.d has been studied in three completed Phase 3 trials: NCT00337610, NCT00397631, and NCT01028391. These trials evaluated the combination in patients with Type 2 Diabetes Mellitus, with enrollments of 190, 520, and 317 patients respectively.
Sitagliptin q.d.+ Pioglitazone q.d is a combination therapy that includes sitagliptin and pioglitazone, administered once daily. It is being studied as a fixed-dose combination for Type 2 Diabetes Mellitus, distinct from the individual drugs used separately.